Colorectal CancerNCT01026753
Innovative Tools to Improve Colorectal Cancer Screening Rates in Manitoba
A study testing Refrigerator Magnet in people with Colorectal Cancer, run by University of Manitoba at 1 site in Canada.
Trial summary
The primary purpose of the study is to investigate the efficacy and effectiveness of a community-based nurse managed telephone support line (Provincial Health Contact Center; PHCC) and Colorectal Cancer Information and Screening Website in supporting Primary Care Providers (PCP) from Winnipeg, Manitoba (Canada) in… Read more about this study
- Who is it for?
- Ages 50 to 74 yearsHealthy volunteers can take part
- Conditions the study is for
- Colorectal Cancer
- What is being tested?
- Refrigerator Magnet
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 2,395 participants
- Where
- 1 siteCanada
- Study dates
- Aug 2010to Dec 2011
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 74 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Average risk men and women
- between the ages of 50 to 74 years
- no symptoms of colorectal cancer
- no personal history of colorectal cancer, polyps or diseases of the colon requiring monitoring by colonoscopy
- includes individuals with one first degree relative with cancer of adenomatous polyps affected at age greater than 60 or two or more second degree relatives with polyps or cancer
Who cannot join
- walk-in patients
- patients having had a flexible sigmoidoscopy or double contrast barium enema within the last 5 years
- patients having had a colonoscopy within the last 10 years.
Trial locations and contacts
1 site in 1 country.
About this study
The primary purpose of the study is to investigate the efficacy and effectiveness of a community-based nurse managed telephone support line (Provincial Health Contact Center; PHCC) and Colorectal Cancer Information and Screening Website in supporting Primary Care Providers (PCP) from Winnipeg, Manitoba (Canada) in their efforts to improve colorectal cancer (CRC) screening Fecal Occult Blood Test (FOBT) compliance in average risk men and women 50-74 years of age. Secondary outcomes of the study involve documenting and investigating common patient questions and comments about CRC and the FOBT during their PHCC communication(s)/Website visits as well as procuring feedback from PCP and patients related to their experiences with the study protocol (PCP), FOBT (patients) and PHCC/website (patients).
Read the detailed description
Primary care providers (PCP) will be recruited within the Winnipeg Regional Health Authority (WRHA) community areas of St. James Assiniboia, Assiniboine South, Downtown, River Heights, Fort Garry, St. Vital and St. Boniface. The first step in recruiting PCP within the WRHA will involve a pre-collaboration call to PCP/clinics to make them aware that the study coordinator will be dropping off a a PCP Collaboration Letter that briefly outlines the proposed research study and requests the participation of PCP. The letter will inquire as to whether the PCP/clinic would be interested in collaborating on the study as well as the best date, time and method of contacting the office. Based on this information, the study coordinator will contact each clinic in the preferred manner to set a date and time to determine their interest in study collaboration and, if so, to set a date and time for a site visit to discuss the study protocol and PCP/clinic involvement and responsibilities.
Once a PCP/clinic has agreed to collaborate on the study, a PCP/Clinic Characterization Form will be completed by the study coordinator. The purpose of this form is to document the routine standard of care provided by each PCP in regards to CRC screening practices with the FOBT and to ensure minimal obtrusiveness of the study protocol in the daily functioning of the PCP/clinic. It is believed that, in Winnipeg, two standard methods of having patients complete an FOBT exist; laboratory requisition filled out by the PCP or direct distribution of the FOBT kit by the PCP to the patient. By filling out the PCP/Clinic Characterization Form, the preferred method of FOBT screening by each PCP/clinic will be documented. This factor will be taken into account as a covariate in the statistical analysis of the data. All PCP within a medical clinic will be randomly allocated to one of two study groups (control or intervention). In the case of medical clinics where there are sub-groupings of PCP/staff that function as a single/separate unit/entity, each sub-group of PCPs will be randomized separately. The objective of customizing this portion of the study protocol to each PCP/clinic is to optimize collaboration with PCPs as well as simulate "real world" PCP practices resulting in evidence-based findings that are able to be integrated into practice.
Collaborating PCP/clinics will be randomly allocated into providing their average risk male and female patients (50-74 years) with either the control or the intervention protocol for FOBT screening for CRC. As there is one type of control group and one study intervention (provision of a magnet with contact information for a Provincial Health Contact Center (PHCC) and Colorectal Cancer Information and FOBT Screening Website) there are a total of two study groups: (1) FOBT recommendation based on usual PCP practice, and (2) FOBT recommendation based on usual PCP practice + magnet. Once a PCP/Clinic is randomized into a group, all their patients will participate in that study group.
Upon arrival for their periodic health examination (PHE) appointment, eligible patients in all study groups will be asked by a front desk clinic support staff employee to complete an In-Clinic Patient Survey/Consent Form related to their exposure to Provincial CRC Screening initiatives (CancerCare Manitoba; ColonCheck) and whether they have completed an FOBT in conjunction with the CancerCare Manitoba Screening Program in the last two years.
During their PHE, the PCP will determine patient eligibility according to the criteria outlined by the study coordinator during the site visit. PCPs in the control group will provide patients with a laboratory requisition indicating an FOBT or directly provide the FOBT kit to patients. Those patients who have a lab requisition indicating FOBT will receive the FOBT kit from the laboratory. PCP in the control and intervention groups will be provided with Patient Tracking Forms (one per patient) on which the PCP will indicate the patient name and date of FOBT requisition/distribution. Each Patient Tracking Form will have a removable sticker with a unique patient study identification number. The PCP will remove the sticker from the Patient Tracking Form and place it on the patient's In-Clinic Survey which will allow researchers to link the data. Study identification numbers that will facilitate patient tracking as well as allow the study coordinator to determine for each PCP/clinic, the number of patients requested by the PCP/clinic to complete an FOBT. It will also facilitate tracking patients that complete their FOBT. The study coordinator will follow-up with PCP/clinic support staff to determine the patients completing their FOBT. Patients are given four months in which to complete their FOBT. After this time, if the FOBT is not completed, they will be assigned an incomplete according to the intention to treat model. In this way, personal health identification is protected. The study coordinator will contact the PCP/clinics regularly for Patient Tracking Form updates and to foster collaborative relationships between researchers and PCP.
PCP/clinics allocated to the intervention groups will be utilize the same Patient Tracking Forms as described above. Each of the Patient Tracking Form sheets will have a sequentially numbered study magnet attached that the PCP will provide to their patient. The refrigerator magnet contains a study specific PHCC telephone number and Website address as well as a brief message about the importance of the FOBT in early detection of CRC.
The sheets of sequential study identification numbers and the Patient Tracking Forms will facilitate determining the number of patients for which an FOBT was requested and the number of patients provided with a magnet. Patients provided with a magnet will use the number assigned to their magnet to identify themselves with the PHCC nurse at the beginning of every call they make as well as to login to the website. This will allow us to determine how many patients provided with the magnet call the PHCC/use the website as well as the number of times they call/login and their most common questions. The number on the magnet will allow us to determine of those who call/login to the PHCC, the number that complete the FOBT.
A four month follow-up patient survey will be conducted by the PHCC to evaluate patient experience with the PHCC and/or CRC Information and Screening Website as well as possible barriers to FOBT compliance. We will also conduct a survey of PCPs involved in the study to determine their experience with the study protocol and how to better facilitate PCP collaboration in research.
The study has been designed to be two-tailed with an alpha error of 0.05%, a beta error of 10% and a power index of 90%. Current FOBT screening rates in Manitoba are approximately 41.9% (Statistics Canada, 2009). It is believed that an intervention leading to an increase in FOBT screening rates of 15% would be clinically significant as it has been predicted that if approximately 70 % of Canadians aged 50 to 74 had a biennial FOBT, followed up by colonoscopy for positive FOBTs, the CRC mortality rate could be reduced by an estimated 17% (Statistics Canada, 2009). A logistic regression of a binary response variable (Y) on a binary independent variable (X) with a sample size of 716 observations [of which 80% are in the group that does not utilize the supplied intervention/magnet PHCC or Website (X=0) and 20% are in the group that does utilize the intervention/magnet PHCC or Website (X=1)] achieves 90% power at a 0.05 significance level to detect a change in Prob(Y=1) from the baseline value of 0.400 to 0.550. This change corresponds to an odds ratio of 1.833.
A biostatistician will be involved in the statistical analysis of results. Analysis of results will be based on the Intention to Treat Model. Therefore, patients not returning their FOBT test within a period of four months will be scored as failing to complete the FOBT test. Categorical variables will be compared using the Chi-square test or Fisher's exact test. The time taken to return FOBT cards will be estimated using Kaplan-Meier analysis. Statistical analysis will be performed using SAS or SPSS Software.
All forms provided to the PCP/Clinics will be collected by the study coordinator at the end of the study.
- Conditions
- Colorectal Cancer
- Being tested
- Refrigerator Magnet
- Keywords
- colorectal cancer, screening, fecal occult blood test, randomized control trial, primary care oncology, web site, provincial health contact center
- Medical subject headings
- Colorectal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Refrigerator MagnetBehavioural
The refrigerator magnet contains a telephone number for a Provincial Health Contact Centre and a URL for a colorectal cancer Website that patients can access to learn more about colorectal cancer, screening and the fecal occult blood test. Patients can also have their questions answered.
| Study group | Role | What they receive |
|---|---|---|
| FOBT by laboratory requisition or directly by PCP | No intervention | The family physician indicates fecal occult blood test on the patient's laboratory requisition (i.e. the patient receives the fecal occult blood test at the lab) or provides the patient with an FOBT kit. |
| FOBT by lab req. or directly from PCP + study magnet | Experimental | The family physician indicates fecal occult blood test on the patient's laboratory requisition (i.e. the patient receives the fecal occult blood test at the lab) or provides the patient with an FOBT kit. The family physician provides each patient with a study magnet containing a PHCC telephone number and study specific website address. Receives: Behavioral: Refrigerator Magnet |
What is being measured
The primary outcome is the main question the study is designed to answer.
Fecal Occult Blood Test (FOBT) completion rate
Measured: 4 months
Secondary outcomes (1)
The most common patient questions and comments about colorectal cancer, screening, and the fecal occult blood test during the intervention(s). A patient and primary care provider survey.
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Dec 2009 (estimated)
- Study startAug 2010
- Primary completionJul 2011
- Study completionDec 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Colorectal CancerStudies of the same condition, open and under way.
- More trials run by University of ManitobaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 2,395 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Manitoba
- Sponsor type
- University, hospital or other
- Collaborators
- Canadian Institutes of Health Research (CIHR), CancerCare Manitoba
- Responsible party
- Principal investigator, Dr. Alan Katz, University of Manitoba
- Investigators
- Alan Katz, MBChB, CCFP, MSc, Principal investigator, University of ManitobaKathleen M Clouston, Ph.D., Study director, University of Manitoba
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01026753
- Sponsor's protocol ID
- H2009:312
- Status last verified
- Jun 2013
- First submitted
- 2 Dec 2009
- Last updated
- 11 Jun 2013
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Clouston K, Katz A, Martens PJ, Sisler J, Turner D, Lobchuk M, McClement S, Crow G; CIHR/CCMB Team in Primary Care Oncology (PCO-NET). Does access to a colorectal cancer screening website and/or a nurse-managed telephone help line provided to patients by their family physician increase fecal occult blood test uptake?: results from a pragmatic cluster randomized controlled trial. BMC Cancer. 2014 Apr 16;14:263. doi: 10.1186/1471-2407-14-263.
PubMed 24739235Clouston K, Katz A, Martens PJ, Sisler J, Turner D, Lobchuk M, McClement S; CIHR/CCMB Team in Primary Care Oncology (PCO-NET). Does access to a colorectal cancer screening website and/or a nurse-managed telephone help line provided to patients by their family physician increase fecal occult blood test uptake?: A pragmatic cluster randomized controlled trial study protocol. BMC Cancer. 2012 May 17;12:182. doi: 10.1186/1471-2407-12-182.
PubMed 22607726
Study at a glance
From the registry record, last updated by the sponsor on 11 Jun 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Innovative Tools to Improve Colorectal Cancer Screening Rates in Manitoba
- ClinicalTrials.gov ID
- NCT01026753
- Acronym / sponsor ID
- H2009:312
- Conditions
- Colorectal Cancer
- Keywords
- colorectal cancer, screening, fecal occult blood test, randomized control trial, primary care oncology, web site, provincial health contact center
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 2,395 participants (actual)
- Lead sponsor
- University of ManitobaUniversity, hospital or other
- Collaborators
- Canadian Institutes of Health Research (CIHR), CancerCare Manitoba
- Study start
- Aug 2010
- Primary completion
- Jul 2011 (actual)
- Study completion
- Dec 2011 (actual)
- First posted
- 4 Dec 2009 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary purpose of the study is to investigate the efficacy and effectiveness of a community-based nurse managed telephone support line (Provincial Health Contact Center; PHCC) and Colorectal Cancer Information and Screening Website in supporting Primary Care Providers (PCP) from Winnipeg, Manitoba (Canada) in their efforts to improve colorectal cancer (CRC) screening Fecal Occult Blood Test (FOBT) compliance in average risk men and women 50-74 years of age. Secondary outcomes of the study involve documenting and investigating common patient questions and comments about CRC and the FOBT during their PHCC communication(s)/Website visits as well as procuring feedback from PCP and patients related to their experiences with the study protocol (PCP), FOBT (patients) and PHCC/website (patients).
Detailed description
Primary care providers (PCP) will be recruited within the Winnipeg Regional Health Authority (WRHA) community areas of St. James Assiniboia, Assiniboine South, Downtown, River Heights, Fort Garry, St. Vital and St. Boniface. The first step in recruiting PCP within the WRHA will involve a pre-collaboration call to PCP/clinics to make them aware that the study coordinator will be dropping off a a PCP Collaboration Letter that briefly outlines the proposed research study and requests the participation of PCP. The letter will inquire as to whether the PCP/clinic would be interested in collaborating on the study as well as the best date, time and method of contacting the office. Based on this information, the study coordinator will contact each clinic in the preferred manner to set a date and time to determine their interest in study collaboration and, if so, to set a date and time for a site visit to discuss the study protocol and PCP/clinic involvement and responsibilities.
Once a PCP/clinic has agreed to collaborate on the study, a PCP/Clinic Characterization Form will be completed by the study coordinator. The purpose of this form is to document the routine standard of care provided by each PCP in regards to CRC screening practices with the FOBT and to ensure minimal obtrusiveness of the study protocol in the daily functioning of the PCP/clinic. It is believed that, in Winnipeg, two standard methods of having patients complete an FOBT exist; laboratory requisition filled out by the PCP or direct distribution of the FOBT kit by the PCP to the patient. By filling out the PCP/Clinic Characterization Form, the preferred method of FOBT screening by each PCP/clinic will be documented. This factor will be taken into account as a covariate in the statistical analysis of the data. All PCP within a medical clinic will be randomly allocated to one of two study groups (control or intervention). In the case of medical clinics where there are sub-groupings of PCP/staff that function as a single/separate unit/entity, each sub-group of PCPs will be randomized separately. The objective of customizing this portion of the study protocol to each PCP/clinic is to optimize collaboration with PCPs as well as simulate "real world" PCP practices resulting in evidence-based findings that are able to be integrated into practice.
Collaborating PCP/clinics will be randomly allocated into providing their average risk male and female patients (50-74 years) with either the control or the intervention protocol for FOBT screening for CRC. As there is one type of control group and one study intervention (provision of a magnet with contact information for a Provincial Health Contact Center (PHCC) and Colorectal Cancer Information and FOBT Screening Website) there are a total of two study groups: (1) FOBT recommendation based on usual PCP practice, and (2) FOBT recommendation based on usual PCP practice + magnet. Once a PCP/Clinic is randomized into a group, all their patients will participate in that study group.
Upon arrival for their periodic health examination (PHE) appointment, eligible patients in all study groups will be asked by a front desk clinic support staff employee to complete an In-Clinic Patient Survey/Consent Form related to their exposure to Provincial CRC Screening initiatives (CancerCare Manitoba; ColonCheck) and whether they have completed an FOBT in conjunction with the CancerCare Manitoba Screening Program in the last two years.
During their PHE, the PCP will determine patient eligibility according to the criteria outlined by the study coordinator during the site visit. PCPs in the control group will provide patients with a laboratory requisition indicating an FOBT or directly provide the FOBT kit to patients. Those patients who have a lab requisition indicating FOBT will receive the FOBT kit from the laboratory. PCP in the control and intervention groups will be provided with Patient Tracking Forms (one per patient) on which the PCP will indicate the patient name and date of FOBT requisition/distribution. Each Patient Tracking Form will have a removable sticker with a unique patient study identification number. The PCP will remove the sticker from the Patient Tracking Form and place it on the patient's In-Clinic Survey which will allow researchers to link the data. Study identification numbers that will facilitate patient tracking as well as allow the study coordinator to determine for each PCP/clinic, the number of patients requested by the PCP/clinic to complete an FOBT. It will also facilitate tracking patients that complete their FOBT. The study coordinator will follow-up with PCP/clinic support staff to determine the patients completing their FOBT. Patients are given four months in which to complete their FOBT. After this time, if the FOBT is not completed, they will be assigned an incomplete according to the intention to treat model. In this way, personal health identification is protected. The study coordinator will contact the PCP/clinics regularly for Patient Tracking Form updates and to foster collaborative relationships between researchers and PCP.
PCP/clinics allocated to the intervention groups will be utilize the same Patient Tracking Forms as described above. Each of the Patient Tracking Form sheets will have a sequentially numbered study magnet attached that the PCP will provide to their patient. The refrigerator magnet contains a study specific PHCC telephone number and Website address as well as a brief message about the importance of the FOBT in early detection of CRC.
The sheets of sequential study identification numbers and the Patient Tracking Forms will facilitate determining the number of patients for which an FOBT was requested and the number of patients provided with a magnet. Patients provided with a magnet will use the number assigned to their magnet to identify themselves with the PHCC nurse at the beginning of every call they make as well as to login to the website. This will allow us to determine how many patients provided with the magnet call the PHCC/use the website as well as the number of times they call/login and their most common questions. The number on the magnet will allow us to determine of those who call/login to the PHCC, the number that complete the FOBT.
A four month follow-up patient survey will be conducted by the PHCC to evaluate patient experience with the PHCC and/or CRC Information and Screening Website as well as possible barriers to FOBT compliance. We will also conduct a survey of PCPs involved in the study to determine their experience with the study protocol and how to better facilitate PCP collaboration in research.
The study has been designed to be two-tailed with an alpha error of 0.05%, a beta error of 10% and a power index of 90%. Current FOBT screening rates in Manitoba are approximately 41.9% (Statistics Canada, 2009). It is believed that an intervention leading to an increase in FOBT screening rates of 15% would be clinically significant as it has been predicted that if approximately 70 % of Canadians aged 50 to 74 had a biennial FOBT, followed up by colonoscopy for positive FOBTs, the CRC mortality rate could be reduced by an estimated 17% (Statistics Canada, 2009). A logistic regression of a binary response variable (Y) on a binary independent variable (X) with a sample size of 716 observations [of which 80% are in the group that does not utilize the supplied intervention/magnet PHCC or Website (X=0) and 20% are in the group that does utilize the intervention/magnet PHCC or Website (X=1)] achieves 90% power at a 0.05 significance level to detect a change in Prob(Y=1) from the baseline value of 0.400 to 0.550. This change corresponds to an odds ratio of 1.833.
A biostatistician will be involved in the statistical analysis of results. Analysis of results will be based on the Intention to Treat Model. Therefore, patients not returning their FOBT test within a period of four months will be scored as failing to complete the FOBT test. Categorical variables will be compared using the Chi-square test or Fisher's exact test. The time taken to return FOBT cards will be estimated using Kaplan-Meier analysis. Statistical analysis will be performed using SAS or SPSS Software.
All forms provided to the PCP/Clinics will be collected by the study coordinator at the end of the study.
Study design
- Primary purpose
- Screening
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| FOBT by laboratory requisition or directly by PCP | No intervention | –The family physician indicates fecal occult blood test on the patient's laboratory requisition (i.e. the patient receives the fecal occult blood test at the lab) or provides the patient with an FOBT kit. |
| FOBT by lab req. or directly from PCP + study magnet | Experimental | Behavioral: Refrigerator MagnetThe family physician indicates fecal occult blood test on the patient's laboratory requisition (i.e. the patient receives the fecal occult blood test at the lab) or provides the patient with an FOBT kit. The family physician provides each patient with a study magnet containing a PHCC telephone number and study specific website address. |
Who may qualify
- Ages
- 50 to 74 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Average risk men and women
- between the ages of 50 to 74 years
- no symptoms of colorectal cancer
- no personal history of colorectal cancer, polyps or diseases of the colon requiring monitoring by colonoscopy
- includes individuals with one first degree relative with cancer of adenomatous polyps affected at age greater than 60 or two or more second degree relatives with polyps or cancer
Key exclusion criteria (3 listed)
- walk-in patients
- patients having had a flexible sigmoidoscopy or double contrast barium enema within the last 5 years
- patients having had a colonoscopy within the last 10 years.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Refrigerator MagnetThe refrigerator magnet contains a telephone number for a Provincial Health Contact Centre and a URL for a colorectal cancer Website that patients can access to learn more about colorectal cancer, screening and the fecal occult blood test. Patients can also have their questions answered. | Behavioural | FOBT by lab req. or directly from PCP + study magnet |
Primary outcome
Fecal Occult Blood Test (FOBT) completion rate
Time frame: 4 months
1 secondary outcome
The most common patient questions and comments about colorectal cancer, screening, and the fecal occult blood test during the intervention(s). A patient and primary care provider survey.
Time frame: 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Jun 2013.
- Derived from this study: PubMed 24739235Clouston K, Katz A, Martens PJ, Sisler J, Turner D, Lobchuk M, McClement S, Crow G; CIHR/CCMB Team in Primary Care Oncology (PCO-NET). Does access to a colorectal cancer screening website and/or a nurse-managed telephone help line provided to patients by their family physician increase fecal occult blood test uptake?: results from a pragmatic cluster randomized controlled trial. BMC Cancer. 2014 Apr 16;14:263. doi: 10.1186/1471-2407-14-263.
- Derived from this study: PubMed 22607726Clouston K, Katz A, Martens PJ, Sisler J, Turner D, Lobchuk M, McClement S; CIHR/CCMB Team in Primary Care Oncology (PCO-NET). Does access to a colorectal cancer screening website and/or a nurse-managed telephone help line provided to patients by their family physician increase fecal occult blood test uptake?: A pragmatic cluster randomized controlled trial study protocol. BMC Cancer. 2012 May 17;12:182. doi: 10.1186/1471-2407-12-182.
- BMC Cancer (Published Protocol)Link provided by the sponsor.
Related trials for Colorectal Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingObservational study
Pre- and On-treatment Multi-omics Profiling of Locally Advanced Rectal Cancer
Rectal Neoplasms
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 2
Tislelizumab in People With Colorectal Cancer
Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alan Katz, MBChB, CCFP, MSc principal investigator
University of Manitoba
Kathleen M Clouston, Ph.D. study director
University of Manitoba
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Refrigerator Magnet in people with Colorectal Cancer, run by University of Manitoba at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Jun 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Fecal Occult Blood Test (FOBT) completion rate (time frame: 4 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01026753, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jun 2013.